Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics.

Adamson H, Nicholl A, Tiede C, Tang AA, Davidson A, Curd H, Wignall A, Ford R, Nuttall J, McPherson MJ, Johnson M, Tomlinson DC.

Biotechniques. 2019 Dec;67(6):261-269. doi: 10.2144/btn-2019-0089. Epub 2019 Sep 5.

2.

Affimer-Enzyme-Inhibitor Switch Sensor for Rapid Wash-free Assays of Multimeric Proteins.

Adamson H, Ajayi MO, Campbell E, Brachi E, Tiede C, Tang AA, Adams TL, Ford R, Davidson A, Johnson M, McPherson MJ, Tomlinson DC, Jeuken LJC.

ACS Sens. 2019 Nov 22;4(11):3014-3022. doi: 10.1021/acssensors.9b01574. Epub 2019 Oct 17.

3.

Affimer reagents as tools in diagnosing plant virus diseases.

Hesketh EL, Tiede C, Adamson H, Adams TL, Byrne MJ, Meshcheriakova Y, Kruse I, McPherson MJ, Lomonossoff GP, Tomlinson DC, Ranson NA.

Sci Rep. 2019 May 17;9(1):7524. doi: 10.1038/s41598-019-43945-6.

4.

Control of conformation in α-helix mimicking aromatic oligoamide foldamers through interactions between adjacent side-chains.

Arrata I, Grison CM, Coubrough HM, Prabhakaran P, Little MA, Tomlinson DC, Webb ME, Wilson AJ.

Org Biomol Chem. 2019 Apr 10;17(15):3861-3867. doi: 10.1039/c9ob00123a.

5.

Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.

Kearney KJ, Pechlivani N, King R, Tiede C, Phoenix F, Cheah R, Macrae FL, Simmons KJ, Manfield IW, Smith KA, Spurgeon BEJ, Naseem KM, Ariens RAS, McPherson MJ, Tomlinson DC, Ajjan RA.

Blood. 2019 Mar 14;133(11):1233-1244. doi: 10.1182/blood-2018-06-856195. Epub 2018 Dec 13.

6.

Site-Specific Labeling of Affimers for DNA-PAINT Microscopy.

Schlichthaerle T, Eklund AS, Schueder F, Strauss MT, Tiede C, Curd A, Ries J, Peckham M, Tomlinson DC, Jungmann R.

Angew Chem Int Ed Engl. 2018 Aug 20;57(34):11060-11063. doi: 10.1002/anie.201804020. Epub 2018 Jul 15.

7.

Sensitive and selective Affimer-functionalised interdigitated electrode-based capacitive biosensor for Her4 protein tumour biomarker detection.

Zhurauski P, Arya SK, Jolly P, Tiede C, Tomlinson DC, Ko Ferrigno P, Estrela P.

Biosens Bioelectron. 2018 Jun 15;108:1-8. doi: 10.1016/j.bios.2018.02.041. Epub 2018 Feb 21.

8.

Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer.

Martin HL, Bedford R, Heseltine SJ, Tang AA, Haza KZ, Rao A, McPherson MJ, Tomlinson DC.

N Biotechnol. 2018 Oct 25;45:28-35. doi: 10.1016/j.nbt.2018.02.008. Epub 2018 Feb 21. Review.

9.

Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action.

Robinson JI, Baxter EW, Owen RL, Thomsen M, Tomlinson DC, Waterhouse MP, Win SJ, Nettleship JE, Tiede C, Foster RJ, Owens RJ, Fishwick CWG, Harris SA, Goldman A, McPherson MJ, Morgan AW.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E72-E81. doi: 10.1073/pnas.1707856115. Epub 2017 Dec 15.

10.

Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technology.

Hughes DJ, Tiede C, Penswick N, Tang AA, Trinh CH, Mandal U, Zajac KZ, Gaule T, Howell G, Edwards TA, Duan J, Feyfant E, McPherson MJ, Tomlinson DC, Whitehouse A.

Sci Signal. 2017 Nov 14;10(505). pii: eaaj2005. doi: 10.1126/scisignal.aaj2005.

11.

Isolation of isoform-specific binding proteins (Affimers) by phage display using negative selection.

Tang AA, Tiede C, Hughes DJ, McPherson MJ, Tomlinson DC.

Sci Signal. 2017 Nov 14;10(505). pii: eaan0868. doi: 10.1126/scisignal.aan0868.

12.

Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.

Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W.

Sci Rep. 2017 Aug 29;7(1):9608. doi: 10.1038/s41598-017-10083-w.

13.

Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function.

Smith GA, Fearnley GW, Abdul-Zani I, Wheatcroft SB, Tomlinson DC, Harrison MA, Ponnambalam S.

Biol Open. 2017 Oct 15;6(10):1404-1415. doi: 10.1242/bio.027896.

14.

Alternative reagents to antibodies in imaging applications.

Bedford R, Tiede C, Hughes R, Curd A, McPherson MJ, Peckham M, Tomlinson DC.

Biophys Rev. 2017 Aug;9(4):299-308. doi: 10.1007/s12551-017-0278-2. Epub 2017 Jul 27. Review.

15.

Affimer proteins are versatile and renewable affinity reagents.

Tiede C, Bedford R, Heseltine SJ, Smith G, Wijetunga I, Ross R, AlQallaf D, Roberts AP, Balls A, Curd A, Hughes RE, Martin H, Needham SR, Zanetti-Domingues LC, Sadigh Y, Peacock TP, Tang AA, Gibson N, Kyle H, Platt GW, Ingram N, Taylor T, Coletta LP, Manfield I, Knowles M, Bell S, Esteves F, Maqbool A, Prasad RK, Drinkhill M, Bon RS, Patel V, Goodchild SA, Martin-Fernandez M, Owens RJ, Nettleship JE, Webb ME, Harrison M, Lippiat JD, Ponnambalam S, Peckham M, Smith A, Ferrigno PK, Johnson M, McPherson MJ, Tomlinson DC.

Elife. 2017 Jun 27;6. pii: e24903. doi: 10.7554/eLife.24903.

16.

Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers.

Arrata I, Barnard A, Tomlinson DC, Wilson AJ.

Chem Commun (Camb). 2017 Mar 2;53(19):2834-2837. doi: 10.1039/c6cc09395g.

17.

Antibody Mimetics for the Detection of Small Organic Compounds Using a Quartz Crystal Microbalance.

Koutsoumpeli E, Tiede C, Murray J, Tang A, Bon RS, Tomlinson DC, Johnson S.

Anal Chem. 2017 Mar 7;89(5):3051-3058. doi: 10.1021/acs.analchem.6b04790. Epub 2017 Feb 15.

18.

Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases.

Webster PJ, Littlejohns AT, Gaunt HJ, Young RS, Rode B, Ritchie JE, Stead LF, Harrison S, Droop A, Martin HL, Tomlinson DC, Hyman AJ, Appleby HL, Boxall S, Bruns AF, Li J, Prasad RK, Lodge JPA, Burke DA, Beech DJ.

Oncotarget. 2017 Jun 27;8(26):42288-42299. doi: 10.18632/oncotarget.15039.

19.

A place for precision medicine in bladder cancer: targeting the FGFRs.

di Martino E, Tomlinson DC, Williams SV, Knowles MA.

Future Oncol. 2016 Oct;12(19):2243-63. doi: 10.2217/fon-2016-0042. Epub 2016 Jul 6. Review.

20.

Chapter Eight - Ubiquitin-Mediated Regulation of Cellular Responses to Vascular Endothelial Growth Factors.

Smith GA, Tomlinson DC, Harrison MA, Ponnambalam S.

Prog Mol Biol Transl Sci. 2016;141:313-38. doi: 10.1016/bs.pmbts.2016.02.006. Epub 2016 Mar 25. Review.

PMID:
27378761
21.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

22.

VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis.

Fearnley GW, Smith GA, Abdul-Zani I, Yuldasheva N, Mughal NA, Homer-Vanniasinkam S, Kearney MT, Zachary IC, Tomlinson DC, Harrison MA, Wheatcroft SB, Ponnambalam S.

Biol Open. 2016 May 15;5(5):571-83. doi: 10.1242/bio.017434.

23.

Trivalent Gd-DOTA reagents for modification of proteins.

Fisher MJ, Williamson DJ, Burslem GM, Plante JP, Manfield IW, Tiede C, Ault JR, Stockley PG, Plein S, Maqbool A, Tomlinson DC, Foster R, Warriner SL, Bon RS.

RSC Adv. 2015 Dec 9;5(116):96194-96200. Epub 2015 Nov 11.

24.

Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity.

Sharma R, Deacon SE, Nowak D, George SE, Szymonik MP, Tang AAS, Tomlinson DC, Davies AG, McPherson MJ, Wälti C.

Biosens Bioelectron. 2016 Jun 15;80:607-613. doi: 10.1016/j.bios.2016.02.028. Epub 2016 Feb 11.

25.

Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions.

Barnard A, Long K, Martin HL, Miles JA, Edwards TA, Tomlinson DC, Macdonald A, Wilson AJ.

Angew Chem Weinheim Bergstr Ger. 2015 Mar 2;127(10):3003-3008. Epub 2015 Jan 30.

26.

VEGFR2 Trafficking, Signaling and Proteolysis is Regulated by the Ubiquitin Isopeptidase USP8.

Smith GA, Fearnley GW, Abdul-Zani I, Wheatcroft SB, Tomlinson DC, Harrison MA, Ponnambalam S.

Traffic. 2016 Jan;17(1):53-65. doi: 10.1111/tra.12341. Epub 2015 Dec 2.

27.

Phage display selected magnetite interacting Adhirons for shape controlled nanoparticle synthesis.

Rawlings AE, Bramble JP, Tang AAS, Somner LA, Monnington AE, Cooke DJ, McPherson MJ, Tomlinson DC, Staniland SS.

Chem Sci. 2015 Oct 1;6(10):5586-5594. doi: 10.1039/c5sc01472g. Epub 2015 Jun 30.

28.

The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis.

Smith GA, Fearnley GW, Tomlinson DC, Harrison MA, Ponnambalam S.

Biosci Rep. 2015 Aug 18;35(5). pii: e00253. doi: 10.1042/BSR20150171. Review.

29.

An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes.

Wheway G, Schmidts M, Mans DA, Szymanska K, Nguyen TT, Racher H, Phelps IG, Toedt G, Kennedy J, Wunderlich KA, Sorusch N, Abdelhamed ZA, Natarajan S, Herridge W, van Reeuwijk J, Horn N, Boldt K, Parry DA, Letteboer SJF, Roosing S, Adams M, Bell SM, Bond J, Higgins J, Morrison EE, Tomlinson DC, Slaats GG, van Dam TJP, Huang L, Kessler K, Giessl A, Logan CV, Boyle EA, Shendure J, Anazi S, Aldahmesh M, Al Hazzaa S, Hegele RA, Ober C, Frosk P, Mhanni AA, Chodirker BN, Chudley AE, Lamont R, Bernier FP, Beaulieu CL, Gordon P, Pon RT, Donahue C, Barkovich AJ, Wolf L, Toomes C, Thiel CT, Boycott KM, McKibbin M, Inglehearn CF; UK10K Consortium; University of Washington Center for Mendelian Genomics, Stewart F, Omran H, Huynen MA, Sergouniotis PI, Alkuraya FS, Parboosingh JS, Innes AM, Willoughby CE, Giles RH, Webster AR, Ueffing M, Blacque O, Gleeson JG, Wolfrum U, Beales PL, Gibson T, Doherty D, Mitchison HM, Roepman R, Johnson CA.

Nat Cell Biol. 2015 Aug;17(8):1074-1087. doi: 10.1038/ncb3201. Epub 2015 Jul 13.

30.

Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies.

Kyle HF, Wickson KF, Stott J, Burslem GM, Breeze AL, Tiede C, Tomlinson DC, Warriner SL, Nelson A, Wilson AJ, Edwards TA.

Mol Biosyst. 2015 Oct;11(10):2738-49. doi: 10.1039/c5mb00284b.

31.

Development and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studies.

Nash CE, Mavria G, Baxter EW, Holliday DL, Tomlinson DC, Treanor D, Novitskaya V, Berditchevski F, Hanby AM, Speirs V.

Oncotarget. 2015 May 30;6(15):13731-41.

32.

Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease.

Smith GA, Fearnley GW, Harrison MA, Tomlinson DC, Wheatcroft SB, Ponnambalam S.

J Inherit Metab Dis. 2015 Jul;38(4):753-63. doi: 10.1007/s10545-015-9838-4. Epub 2015 Apr 14. Review.

PMID:
25868665
33.

Selective and potent proteomimetic inhibitors of intracellular protein-protein interactions.

Barnard A, Long K, Martin HL, Miles JA, Edwards TA, Tomlinson DC, Macdonald A, Wilson AJ.

Angew Chem Int Ed Engl. 2015 Mar 2;54(10):2960-5. doi: 10.1002/anie.201410810. Epub 2015 Feb 4.

34.

Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications.

Tiede C, Tang AA, Deacon SE, Mandal U, Nettleship JE, Owen RL, George SE, Harrison DJ, Owens RJ, Tomlinson DC, McPherson MJ.

Protein Eng Des Sel. 2014 May;27(5):145-55. doi: 10.1093/protein/gzu007. Epub 2014 Mar 25.

35.

Multidrug-resistant breast cancer: current perspectives.

Martin HL, Smith L, Tomlinson DC.

Breast Cancer (Dove Med Press). 2014 Jan 10;6:1-13. doi: 10.2147/BCTT.S37638. eCollection 2014. Review.

36.

High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers.

Martin HL, Adams M, Higgins J, Bond J, Morrison EE, Bell SM, Warriner S, Nelson A, Tomlinson DC.

PLoS One. 2014 Feb 5;9(2):e88338. doi: 10.1371/journal.pone.0088338. eCollection 2014.

37.

The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function.

Stadler LK, Tomlinson DC, Lee T, Knowles MA, Ko Ferrigno P.

Cell Death Dis. 2014 Jan 30;5:e1037. doi: 10.1038/cddis.2013.564.

38.

Vascular endothelial growth factor A-stimulated signaling from endosomes in primary endothelial cells.

Fearnley GW, Smith GA, Odell AF, Latham AM, Wheatcroft SB, Harrison MA, Tomlinson DC, Ponnambalam S.

Methods Enzymol. 2014;535:265-92. doi: 10.1016/B978-0-12-397925-4.00016-X.

39.

A high-throughput assay to identify modifiers of premature chromosome condensation.

Adams M, Cookson VJ, Higgins J, Martin HL, Tomlinson DC, Bond J, Morrison EE, Bell SM.

J Biomol Screen. 2014 Jan;19(1):176-83. doi: 10.1177/1087057113495443. Epub 2013 Aug 27.

40.

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.

di Martino E, Tomlinson DC, Knowles MA.

Adv Urol. 2012;2012:429213. doi: 10.1155/2012/429213. Epub 2012 Jul 31.

41.

FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms.

Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA.

PLoS One. 2012;7(6):e38972. doi: 10.1371/journal.pone.0038972. Epub 2012 Jun 12.

42.

Mechanisms of FGFR3 actions in endocrine resistant breast cancer.

Tomlinson DC, Knowles MA, Speirs V.

Int J Cancer. 2012 Jun 15;130(12):2857-66. doi: 10.1002/ijc.26304. Epub 2011 Aug 29.

43.

Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant.

Stadler LK, Hoffmann T, Tomlinson DC, Song Q, Lee T, Busby M, Nyathi Y, Gendra E, Tiede C, Flanagan K, Cockell SJ, Wipat A, Harwood C, Wagner SD, Knowles MA, Davis JJ, Keegan N, Ferrigno PK.

Protein Eng Des Sel. 2011 Sep;24(9):751-63. doi: 10.1093/protein/gzr019. Epub 2011 May 25.

PMID:
21616931
44.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA.

Br J Cancer. 2011 Jan 4;104(1):75-82. doi: 10.1038/sj.bjc.6606016. Epub 2010 Nov 30.

45.

Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer.

Tomlinson DC, Knowles MA.

Am J Pathol. 2010 Nov;177(5):2379-86. doi: 10.2353/ajpath.2010.100354. Epub 2010 Oct 1.

46.

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

di Martino E, L'Hôte CG, Kennedy W, Tomlinson DC, Knowles MA.

Oncogene. 2009 Dec 3;28(48):4306-16. doi: 10.1038/onc.2009.280. Epub 2009 Sep 14.

47.

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.

Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA.

Cancer Res. 2009 Jun 1;69(11):4613-20. doi: 10.1158/0008-5472.CAN-08-2816. Epub 2009 May 19.

48.

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification.

Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA.

Oncogene. 2008 Apr 24;27(19):2716-27. Epub 2007 Nov 26.

49.
50.

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Tomlinson DC, Hurst CD, Knowles MA.

Oncogene. 2007 Aug 30;26(40):5889-99. Epub 2007 Mar 26.

Supplemental Content

Loading ...
Support Center